earnings
confidence high
sentiment negative
materiality 0.75
Biote Q1 revenue $44.9M (-8.3% YoY); net income $2.7M vs $15.8M, hit by hormone pellet recall
biote Corp.
2026-Q1 EPS reported
$0.06
revenue$44,935,000
- Revenue $44.9M, down 8.3% YoY; net income $2.7M ($0.06 EPS) vs $15.8M ($0.37) in Q1 2025.
- Procedure revenue fell 13.2% to $31.3M due to voluntary recall of Asteria Health hormone pellets; supplements up 19.1% to $11.0M.
- Gross margin 68.9% vs 74.3% from higher replacement costs and reduced manufacturing efficiency at Asteria.
- Adjusted EBITDA $8.7M (19.4% margin); sales team expansion nearing target of 120 representatives.
- Management expects return to procedure growth in second half of 2026 after recall impact.
item 2.02item 9.01